On 29 May 2019, orphan designation (EU/3/19/2161) was granted by the European Commission to Worphmed World Orphan Medicines Limited, United Kingdom, for diacerein for the treatment of epidermolysis bullosa.
The sponsorship was transferred to Worphmed World Orphan Medicines Limited, Italy, in August 2019.
|Disease / condition||
Treatment of epidermolysis bullosa
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: